Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Bosco & Crossy's stock picks,talk area -- Ignore unavailable to you. Want to Upgrade?

To: Crossy who wrote (12958)	10/2/2005 11:49:43 AM
From: yassinzineb	Read Replies (2) \| Respond to of 37387

Crossy MEMY I like MEMY because of this: A NOBEL PRIZE WINNING FOUNDER : Eric KANDEL Memory has a very strong management team in place. Upper management has extensive experience in the CNS space from prior positions with large pharmaceutical companies. Particularly notable is the expertise of co-founder and chairman of the scientific advisory board, Eric Kandel. Dr. Kandel has received the prestigious Lasker Award for work in the molecular biology of memory acquisition and storage, and shares the 2000 Nobel Prize for Medicine for work in signal transduction. TAKE A LOOK at the insiders activity: all are open market buys!! marketwatch.com secform4.com Memory Pharmaceuticals Corporation (MEMY). The Company's principal activities are to research and develop innovative drug candidates. The Innovative drug candidates are used for the treatment of central nervous system conditions that exhibit impairment of memory and other cognitive functions. The central nervous system therapies are designed to address biological targets within the cellular pathways. These are involved in memory formation and other cognitive functions. It currently has four clinical and preclinical drug candidates and also multiple drug discovery programs in development. These drugs in development are targeted to treat conditions, such as Alzheimer's disease, vascular dementia and mild-cognitive impairment (MCI) and also include certain psychiatric disorders, such as schizophrenia and depression. It also developing and testing additional compounds that may have potential application to other CNS disorders, such as Parkinson's disease and age associated cognitive decline. We've had this news very recently: «Memory Pharma shares rise on progress for Alzheimer's drug (MEMY) - Shares of Memory Pharmaceuticals Corp. (MEMY) rose 38 cents, or 21% to $2.21 after the company reported progress in its in-research development of a treatment for Alzheimer's. The Montvale, N.J. company said it expects to commence treating patients with mild to moderate Alzheimer's disease in a Phase 2a clinical trial over the next several weeks after completing the dosing portion of a safety and tolerability study of its MEM 1003 drug. MEM 1003 works by reestablishing normal levels of calcium in patients affected by the neurogenerative disorder leading to an improvement in cognition and a reduction in the progression of the disease.» There were some more news, but this was the one that put the stock in motion. Volume was the highest on the stock's history and that usually means something. Something bullish. fool.com 1 Month intraday chart: stockcharts.com[f,a]fhcayiay[d20][pc50!b200!f][vc60]<i[j5998879..